However, while low-dose anti-VEGFR2 therapy in orthotopic mPDAC impacts the structure of tumour vessels by enhancing the pericyte coverage, as previously described in other tumour types [40,62], differently from N6L, low-dose anti-VEGFR2 was not able to impact the proportion of Tregs or MDSCs. Here, KDR is linked to neoplasm.